19 participants
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-12-12
- Start Date:
- 2021-04-09
- Completion:
- 2024-11-15
Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent T-Cell Prolymphocytic Leukemia
- Refractory Acute Biphenotypic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory T-Cell Prolymphocytic Leukemia
Interventions
- DRUG
No Results Yet